In 1982, a new spiral Gram-negative bacterium which was similar to those of the genus Campylobacter was isolated from the gastric mucosa of 11 patients with gastritis. From then on, the organism was isolated in a further 114 of 267 patients who underwent antral biopsy in Fremantle Hospital between January 1983 and September 1984. During 1984, the bacterium was cultured from 88% of patients in whom it was detected histologically, and was not cultured from any patient with histologically normal gastric mucosa. The new bacterium, pyloric campylobacter, grew in three days on brain-heart infusion blood-agar at 37 degrees C in an atmosphere with added CO2. All isolates tested were sensitive to penicillin, erythromycin, tetracycline, cephalosporins, gentamicin and bismuth citrate; 80% of isolates were sensitive to metronidazole or tinidazole. It is suggested that pyloric campylobacter infection is a major factor in the causation of dyspeptic disease and peptic ulceration. Antibacterial regimens directed against the bacterium may provide a permanent cure for these chronic disorders.
No takes yet. Share an insight, caveat, or question.
Marshall et al. (1985) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: